Compare LSBK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | ACET |
|---|---|---|
| Founded | 1891 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 71.3M |
| IPO Year | 2006 | N/A |
| Metric | LSBK | ACET |
|---|---|---|
| Price | $14.87 | $8.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $136.00 |
| AVG Volume (30 Days) | 9.2K | ★ 201.2K |
| Earning Date | 01-23-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 105.28 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $27,774,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $11.50 | $7.15 |
| 52 Week High | $16.95 | $17.76 |
| Indicator | LSBK | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 98.14 |
| Support Level | $14.66 | $0.47 |
| Resistance Level | $14.98 | $8.84 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.05 | 0.93 |
| Stochastic Oscillator | 27.27 | 95.58 |
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.